Cardiovascular Risk-Benefit Profile of Sibutramine

ISSN： 1175-3277

Source： American Journal of Cardiovascular Drugs, Vol.10, Iss.5, 2010-10, pp. : 321-334

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

When science is not enough – a risk/benefit profile of thiomersal-containing vaccines

By Clements C John McIntyre Peter B

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 17-29

Informa Healthcare

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Sibutramine in the Management of Obesity

By Nisoli E. Carruba M.O.

Drug Safety, Vol. 26, Iss. 14, 2003-01 ,pp. : 1027-1048

Adis International

Access to resources Recommend Favorite

Statin Treatment and the Natural History of Atherosclerotic-Related Diseases: Pathogenic Mechanisms and the Risk-Benefit Profile

Current Pharmaceutical Design, Vol. 10, Iss. 4, 2004-02 ,pp. : 425-432

Bentham Science Publishers

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Abciximab in Angioplasty

By Kleiman N.S.

Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. : 43-57

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Amifostine in Cytoprotection

By Mabro M.

Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. : 367-387

Adis International

Access to resources Recommend Favorite